Informations

The 2025 American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI 2025) successfully concluded on January 25. One of the most closely watched presentations at the conference was the release of results from the EORTC-1203—INNOVATION trial (Abstract LBA331), capturing the attention of oncologists worldwide. Oncology Frontier had the exclusive opportunity to interview Dr. Anna…

The 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2025) was held from February 13 to 15 in San Francisco, showcasing the latest research and treatment strategies in the field of urological oncology from experts worldwide. Several clinical research findings from Dr. Hongqian Guo’s team at Nanjing Drum Tower Hospital were selected…

The NeoSTAR trial, published in March 2024, evaluated neoadjuvant sacituzumab govitecan (SG) in early-stage triple-negative breast cancer (TNBC). This study explored a response-guided approach using SG alone for four cycles.…

Currently, chemotherapy combined with immunotherapy for bladder preservation has met the clinical needs of some muscle-invasive bladder cancer (MIBC) patients, offering a potential balance between effective tumor control and improved quality of life. However, for MIBC patients who are intolerant to platinum-based chemotherapy, bladder-preserving strategies still require further exploration. At the recently held ASCO-GU Annual…

Clear cell renal cell carcinoma (ccRCC) is widely associated with dysregulation of the VHL (Von Hippel-Lindau) pathway, leading to overexpression of HIF-2α, which activates multiple oncogenic pathways. Targeting HIF-2α, with therapies such as belzutifan, has brought new hope to VHL patients and renal cancer patients alike. At this year’s ASCO GU symposium, Urology Frontier invited…